idiopathic Multicentric Castleman Disease
Conditions
Interventions
Case series:PCD regimen
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18-70 years old; 2. Meeting the diagnostic criteria of international consensus on iMCD and the definition of RR-MCD*; 3. Willingness to sign the informed consent form; 4. Expected lifetime over 100 days; 5. No serious cardiac complications such as acute myocardial infarction or heart failure within 6 months; * Refractory MCD: defined as patients who can not reach CR after two standard chemotherapy; Relapsed MCD: refers to those patients with disease progress after remission.
Exclusion criteria
Exclusion criteria: 1. Complicated with other organ dysfunction, such as heart and liver failure; 2. Active tuberculosis, deep fungal infection or viral diseases; 3. Patients with confirmed autoimmune diseases, such as SLE or rheumatoid arthritis; 4. Unwilling to accept regular examination or follow-up; 5. Patients who had received bortezomib or other proteasome inhibitors in the past six months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year PFS;2-year OS;Incidence of infection;Cytokines such as VEGF, IL-6, IL-17; | — |
Countries
China
Contacts
Public ContactDr. Yujun Dong
Peking University First Hospital
Outcome results
None listed